EUVIMEDEUVIMED entdecken
Crossref

How Much Change Is Meaningful in Global Impression Anchors? Evidence From 5 Rare Diseases

Courtney Hurt, Maja Kuharic, Somayeh Hashemi, Eloise Salmon, Sonya Eremenco, David Cella, Karen Kaiser, Chelsea Perschon, Sara Shaunfield, John Devin Peipert

Value in Health · 2026

DOI: 10.1016/j.jval.2026.04.012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Value in Health, 2026. Verfasst von Courtney Hurt und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Social Sciences, Northwestern University, Chicago, IL, USA. Electronic address: courtney.hurt@northwestern.edu. Hauptthemen laut MEDLINE: Rare Diseases, Patient Reported Outcome Measures. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: U.S. Food and Drug Administration, Food and Drug Administration.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Rare diseases pose methodological challenges in determining meaningful change thresholds for clinical outcome assessments (COAs) because of small sample sizes and disease heterogeneity. This article presents qualitative approaches for establishing patient-informed meaningful change thresholds on global impression anchor measures for rare diseases. METHODS: Two Food and Drug Administration-funded studies used novel cognitive debriefing methods to determine within-patient meaningful change on custom-developed anchors. Northwestern University Clinical Outcome Assessment Team debriefed Patient Global Impression of Severity and Change anchors referencing 5 physical function performance outcomes with 34 adults with idiopathic pulmonary fibrosis, systemic sclerosis, or myositis. Prepare-NS developed swelling-related patient-reported outcome and observer-reported outcome measures for nephrotic syndrome using Patient Global Impression of Severity/Global Impression of Severity and Change and Observer Global Impression of Severity/Change anchors with 12 patients and 8 caregivers. RESULTS: Qualitative anchor debriefing proved feasible across rare disease populations and COA types. Though many participants identified smaller (eg, 1-category) changes as meaningful, there was strong variation by anchor type and disease group. Anchors focusing on severity (vs impact) tended to require larger changes to be meaningful. In Prepare-NS, most patient-reported outcome participants and all caregivers viewed "No change" after 3 months of hypothetical treatment negatively. In Northwestern University Clinical Outcome Assessment Team, some participants experienced cognitive difficulties with PerfO anchors, struggling to translate objective metrics into meaningful impact. CONCLUSIONS: Qualitative methods can provide patient-informed meaningful change thresholds on global impression anchors, although patients may struggle to identify meaningful change for performance anchors. Nonetheless, qualitative patient-informed thresholds can inform quantitative COA interpretation and strengthen endpoint development and regulatory dialog in rare disease clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rare DiseasesPatient Reported Outcome MeasuresHumansFemaleSeverity of Illness IndexAdultMiddle AgedMaleScleroderma, SystemicAged

Stichwörter der Autor:innen

anchor-based methodsclinical outcome assessmentsmeaningful changepatient-reported outcomesqualitative methodsrare diseases

Autor:innen und Institutionen

  • Department of Medical Social Sciences, Northwestern University, Chicago, IL, USA. Electronic address: courtney.hurt@northwestern.edu.
  • Department of Medical Social Sciences, Northwestern University, Chicago, IL, USA.
  • Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA.
  • Patient-Reported Outcome Consortium, Critical Path Institute, Tucson, AZ, USA.
  • Clinical Outcomes Solutions, Tucson, AZ, USA.
  • Centre for Patient-Reported Outcomes Research, Department of Applied Health Sciences, University of Birmingham, Edgbaston, Birmingham, England, UK; LifeArc Centre for Acceleration of Rare Disease Trials, Birmingham UK.

Förderung

  • U.S. Food and Drug Administration
  • Food and Drug Administration

Zitieren

APA

Hurt, C., Kuharic, M., Hashemi, S., Salmon, E., Eremenco, S., Cella, D., Kaiser, K., Perschon, C., Shaunfield, S., & Peipert, J. D. (2026). How Much Change Is Meaningful in Global Impression Anchors? Evidence From 5 Rare Diseases. Value in Health. https://doi.org/10.1016/j.jval.2026.04.012

Vancouver

Hurt C, Kuharic M, Hashemi S, Salmon E, Eremenco S, Cella D, et al. How Much Change Is Meaningful in Global Impression Anchors? Evidence From 5 Rare Diseases. Value in Health. 2026. doi:10.1016/j.jval.2026.04.012

BibTeX
@article{Hurt2026,
  author = {Hurt, Courtney and Kuharic, Maja and Hashemi, Somayeh and Salmon, Eloise and Eremenco, Sonya and Cella, David and Kaiser, Karen and Perschon, Chelsea and Shaunfield, Sara and Peipert, John Devin},
  title = {How Much Change Is Meaningful in Global Impression Anchors? Evidence From 5 Rare Diseases},
  journal = {Value in Health},
  year = {2026},
  doi = {10.1016/j.jval.2026.04.012}
}
Kostenlos starten →